A rare clinical case of thyrotoxic hepatitis detected in a pregnant woman is presented. A diagnostic search was carried out to clarify the cause of hepatitis, during which the pathology of the thyroid gland was revealed. The patient was prescribed adequate therapy with a thyrostatic drug, which in a short time allowed to achieve a significant decrease in the activity of the hepatic pathological process, which made it possible to prolong pregnancy.
The presented clinical case demonstrates the appearance of vivid clinical manifestations of Crohn’s disease after a COVID-19 infection. It was not possible to diagnose the disease in the early stages due to the lack of typical symptoms and the necessary examination. A new coronavirus infection acted as a trigger factor for the progression of Crohn’s disease. The diagnosis was confirmed during instrumental and laboratory studies, adequate therapy was prescribed, which led to a rapid relief of the attack of the disease.
We present a rare clinical case of Wilson-C onovalov disease in a patient after a new coronavirus infection. The development of her neurological symptoms, which allowed to specify the etiology of the already existing liver damage, may have been provoked by the COVID-19 infection, in which the central nervous system is frequently involved in the pathological process. Wilson-C onovalov disease was suspected due to the presence of neurological manifestations and signs of liver cirrhosis. Subsequently, the diagnosis was confi rmed genetically, copper metabolism disorders were identifi ed and pathogenetic therapy was prescribed to eliminate excess copper from the body.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.